- Home
- VRCA vs ELUT Comparison
VRCA vs ELUT Comparison
Compare VRCA & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- ELUT
- Stock Information
- Founded
- VRCA 2013
- ELUT 2015
- Country
- VRCA United States
- ELUT United States
- Employees
- VRCA N/A
- ELUT N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- ELUT Medical Specialities
- Sector
- VRCA Health Care
- ELUT Health Care
- Exchange
- VRCA Nasdaq
- ELUT Nasdaq
- Market Cap
- VRCA 80.7M
- ELUT 84.3M
- IPO Year
- VRCA 2018
- ELUT 2020
- Fundamental
- Price
- VRCA $5.99
- ELUT $1.96
- Analyst Decision
- VRCA Hold
- ELUT Strong Buy
- Analyst Count
- VRCA 5
- ELUT 2
- Target Price
- VRCA $6.00
- ELUT $8.00
- AVG Volume (30 Days)
- VRCA 57.3K
- ELUT 27.8K
- Earning Date
- VRCA 08-13-2025
- ELUT 08-06-2025
- Dividend Yield
- VRCA N/A
- ELUT N/A
- EPS Growth
- VRCA N/A
- ELUT N/A
- EPS
- VRCA N/A
- ELUT N/A
- Revenue
- VRCA $7,179,000.00
- ELUT $23,711,000.00
- Revenue This Year
- VRCA $165.25
- ELUT $20.10
- Revenue Next Year
- VRCA $80.06
- ELUT $85.89
- P/E Ratio
- VRCA N/A
- ELUT N/A
- Revenue Growth
- VRCA N/A
- ELUT N/A
- 52 Week Low
- VRCA $3.82
- ELUT $1.61
- 52 Week High
- VRCA $71.40
- ELUT $5.12
- Technical
- Relative Strength Index (RSI)
- VRCA 38.77
- ELUT 47.39
- Support Level
- VRCA $5.86
- ELUT $1.82
- Resistance Level
- VRCA $7.13
- ELUT $2.16
- Average True Range (ATR)
- VRCA 0.88
- ELUT 0.25
- MACD
- VRCA -0.28
- ELUT -0.03
- Stochastic Oscillator
- VRCA 6.01
- ELUT 23.81
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.